← All trials
NCT06078839
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2023
- Primary completion
- Oct 1, 2026
- Completion date
- Oct 1, 2026
- First posted
- Oct 12, 2023
- Last posted
- Oct 12, 2023
- Enrollment
- 778
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- China Medical UniversityLead sponsor
- Benxi City hospital of Chinese medicineCollaborator
- Xinjiang Medical UniversityCollaborator
- China Medical UniversityOverall official - principal investigator
- China Medical UniversitySponsor investigator
- Huludao central hospitalCollaborator
- LanZhou UniversityCollaborator
- Nanjing Medical UniversityCollaborator
- Shanxi Bethune HospitalCollaborator
- Shanxi Medical UniversityCollaborator
- Nantong UniversityCollaborator
- Nanjing UniversityCollaborator
- Gannan Medical UniversityCollaborator
- University of South ChinaCollaborator
- China Medical UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Zhejiang UniversityCollaborator
- Zhejiang UniversityCollaborator
- China Medical UniversityOfficial
- Jilin UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.